Profilaxis postexposición ocupacional al HIV

1. Bangsberg D, Goldshmidt RH. Postexposure prophylaxis for occupational exposure to HIV. JAMA 1999; 283:1623-4.
2. Bangsberg D, Hecht F, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
3. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999 ;354:1084-9.
4. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337:1485–90.
5. Ciesielski CA, Metler RP. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunode_ciency virus. Am J Med 1997; 102(suppl 5B):115–6.
6. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunode_ciency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80. 108
7. Devereus HL, Youle M, Johnson MA, et al. Rapid decline indetectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:123-7.
8. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunode_ciency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-64.
9. Frenkel LM, Cowles MK, Shapiro DE, et al. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother to-infant transmission of human immunode_ciency virus types 1. J Infect Dis 19